When the Signal From Phase 2 Research Should Be a Warning Sign

Howard Jack West^{1

2}

Affiliations

Comment

Howard Jack West. JAMA Oncol. 2021.

. 2021 Mar 1;7(3):394.

doi: 10.1001/jamaoncol.2020.6598.

Howard Jack West^{1

2}

¹ Department of Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, California.
² Web Editor, JAMA Oncology.

No abstract available

Comment on

Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With EGFR T790M-Mutated Non-Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor: West Japan Oncology Group 8715L Phase 2 Randomized Clinical Trial.
Akamatsu H, Toi Y, Hayashi H, Fujimoto D, Tachihara M, Furuya N, Otani S, Shimizu J, Katakami N, Azuma K, Miura N, Nishino K, Hara S, Teraoka S, Morita S, Nakagawa K, Yamamoto N. Akamatsu H, et al. JAMA Oncol. 2021 Mar 1;7(3):386-394. doi: 10.1001/jamaoncol.2020.6758. JAMA Oncol. 2021. PMID: 33410885 Free PMC article. Clinical Trial.